key: cord-0898086-ynr6hkeg authors: Kabaçam, Gökhan; Wahlin, Staffan; Efe, Cumali title: Autoimmune hepatitis triggered by COVID‐19: A report of two cases date: 2021-09-03 journal: Liver Int DOI: 10.1111/liv.15044 sha: b1c6a3c185ac4ad76fb72cfba33dc6392371d418 doc_id: 898086 cord_uid: ynr6hkeg nan Recently, in the Liver International, Marabotto et al, 1 reported a patient who developed autoimmune hepatitis (AIH) during coronavirus disease 2019 . Here, we present two patients who developed high aminotransferases during COVID-19 and were ultimately diagnosed with AIH. The general characteristics and outcome of these patients are summarized in Table 1 . COVID-19 was diagnosed by PCR-based test. Serologies for acute and chronic viral hepatitis (anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HCV, anti-EBV IgM and anti-CMV IgM) were all negative. AIH was diagnosed by the presence of positive autoimmune serology and high serum IgG levels. Immunosuppressive therapy was given during active COVID-19 to one patient but was delayed until the COVID-PCR test became negative in the other patient. Both patients showed good response to immunosuppressive therapy at the time of writing this paper. New-onset or flare of immune-mediated disorders such as Guillain-Barre syndrome, autoimmune haemolytic anaemia and immune thrombocytopenic purpura has been described during or following COVID-19. 2 There is no evidence-based diagnostic algorithm or treatment recommendation for AIH in active COVID-19 patients. 3,4 Some experts suggest that an AIH diagnosis can be made without liver biopsy during COVID-19 if patients have typical laboratory and serological findings. 5 Our two patients had laboratory features strongly suggestive of AIH and we, therefore did not perform liver biopsies. In patients with concomitant AIH and COVID-19, immunosuppressive therapy should be given after weighing potential risks and benefits. Patient 1 had mild features of AIH at presentation and therapy was delayed until COVID-19 PCR test became negative. Patient 2 had a clinically more severe form of AIH and was given immunosuppressive therapy which may be considered life-saving in severe AIH. New-onset liver injury is a commonly observed clinical manifestation of COVID-19. Our two cases along with the report of Marabotto et al highlight that AIH should be considered among different possible diagnoses in subjects who develop elevated aminotransferases during or soon after COVID-19. azathioprine, immunosuppression, liver transplantation, SARS-CoV-2, steroid CE, GK and SW interpreted data and prepared manuscript for the final submission. All relevant data are presented in the manuscript. COVID-19 and liver disease: not all evil comes to harm Autoinflammatory and autoimmune conditions at the crossroad of COVID-19 Feasibility of telehealth in the management of autoimmune hepatitis before and during the COVID-19 pandemic Outcome of COVID-19 in patients with autoimmune hepatitis: an international multicenter study Management of patients with autoimmune liver disease during COVID-19 pandemic